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Ian Holt has put together an outstanding book on the genetics
of mitochondrial disorders. The book offers much more than
clinical correlations of genetic abnormalities. The chapters
were contributed by the best minds in the ﬁeld, and, although
it is a multiauthor book, the chapters were assembled in well-
designed sections to cover the basic biology of mitochondria;
a description of mitochondrial and nuclear DNA mutations in
clinical disorders; the role of mitochondrial dysfunction in cel-
lular function; neurodegenerative disorders and aging; and,
ﬁnally, discussions on therapy, experimental models, and ge-
netic counseling. The editor has clearly put a great deal of
effort into making the chapters complementary and keeping a
seamless thematic ﬂow. Because the book approaches its topics
in depth, it will be an excellent reference book, not only for
physicians and genetic counselors but also for students and
scientists interested in any aspect of mitochondrial biology and
genetics.
Genetics of Mitochondrial Diseases has a very compre-
hensive segment on the basic biology of mitochondria and
mitochondrial DNA (mtDNA), including new concepts on
mtDNA replication, maintenance, repair, recombination, and
expression. It also summarizes very recent ﬁndings on the pro-
tein biosynthetic and proteolytic systems inside mitochondria.
All these aspects are quickly evolving and not yet completely
understood. An update on the mechanisms of protein import
into mitochondria is also provided, as defects in this process
have been associated with deafness and dystonia in Mohr-
Tranebjaerg syndrome. The chemical aspects of oxidative
phosphorylation are described, but in such a clear framework
that even the non–chemically inclined could follow the intri-
cacies of the chemiosmotic theory of ATP synthesis.
The second and third sections deal speciﬁcally with diseases
caused by both mitochondrial and nuclear DNA mutations.
This area has advanced tremendously in the past few years,
and the chapters incorporate the most recent ﬁndings. Both
point mutations and rearrangements of the mtDNA are de-
scribed, including the most recent thoughts on their patho-
geneses. The molecular bases of autosomal dominant multiple
mtDNA deletions and autosomal recessive mtDNA depletions
are examples of mechanisms of mitochondrial diseases in-
volving nuclear-mitochondrial communication, unveiled in the
past few years, that are included in these sections. Identiﬁca-
tions and characterizations of speciﬁc nuclear-coded genes im-
plicated in infantile forms of mitochondrial disorders (e.g.,
Leigh syndrome) are also extensively discussed.
The fourth section addresses the cellular consequences of
oxidative phosphorylation defects and how these alterations—
such as increased reactive oxygen species production and de-
creased calcium buffering capacity—can have a fundamental
role in cellular function. The chapter by Aubrey de Grey feels
like a scholars’ debate in a traditional Cambridge college,
where the involvement of mitochondria in aging is spiritedly
argued and theories are defended, attacked, and proposed. Did
you know that a cell with heteroplasmic mtDNA could have
homochondrous organelles and still maintain a heterokairotic
state?
The ﬁfth and ﬁnal section deals with important aspects of
disease management and future therapies. mtDNA segregation
is quite complex and has important implications about path-
ogenesis. Mitochondrial genomes complementation and dom-
inant effects are other examples of these complex interactions.
In recent years, several animal models of mitochondrial dis-
eases have been created, including a fewwithmutatedmtDNA.
Such models should accelerate the development of new ther-
apies. Current therapies are not discussed in this book. Such
therapies are basically vitamin supplementations that have not
been shown to be effective. They are in the category of “If it
does not harm, why not?” The editor chose instead to present
the state of the art of new therapeutic approaches, particularly
emerging genetic and pharmacogenetic concepts. Prenatal di-
agnosis and genetic management of mitochondrial diseases are
arguably the most important practical consequences of the
scientiﬁc advancements in this ﬁeld. These are discussed in
detail and should guide genetic counselors when they are faced
with these mysterious disorders.
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